CurrentPremera BluecrossPolicy 2.04.509

Cardiovascular Risk Panels

Policy defines medical necessity and coverage stance for cardiovascular risk panels (multi-marker laboratory panels intended to assess cardiac risk, excluding simple lipid panels) including examples, coding guidance, evidence summary, and history for Premera Bluecross. It does not apply to diagnosis of acute myocardial infarction and does not apply to Medicare Advantage.

Policy Summary

PayerPremera Bluecross

PolicyCardiovascular Risk Panels

Policy CodePolicy 2.04.509

Change TypeClarified; Revised (administrative)

Effective DateMar. 1, 2026

Next Review Date

Key ActionProviders should recognize that cardiovascular risk panels (multi-biomarker panels other than simple lipid panels) are considered not medically necessary; documentation of medical necessity for coverage of such panels will not meet policy.

POLICY UPDATE CHANGES

Removed CPT code 81291 from the policy review list as it is reviewed by Carelon.

Policy renumbered from 2.04.100 to 2.04.509 on 05/01/24.

1Medical Necessity Position (not medically necessary)

12Example Panels Listed

12Component CPT/Proprietary Codes Listed

Coverage Summary

Cardiovascular risk panels are multi-marker laboratory tests that report results of multiple individual biomarkers (lipids, inflammatory markers, metabolic parameters, genetic markers, and others) intended to refine assessment of future cardiovascular disease risk. These panels differ from a simple lipid panel, which is generally composed of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides (and sometimes calculated ratios such as total/HDL cholesterol).

Evidence to date shows many biomarkers and panels have predictive associations with cardiovascular disease, but the literature lacks randomized controlled trials demonstrating that use of cardiovascular risk panels leads to improved clinical outcomes compared with standard risk assessment. The policy history and evidence review note multiple cohort and case-control studies and systematic reviews reporting predictive performance but conclude that evidence of clinical utility (changes in management leading to better outcomes) is insufficient.

Medical Necessity Determinations

Medical Necessity Determination

Cardiovascular risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels*) are considered not medically necessary.

Panel definition and intended use

Test is a cardiovascular risk panel consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels)
Use is for risk assessment of developing cardiovascular disease (not diagnosis of acute myocardial infarction)

Not Covered / Experimental

Coverage stance: Cardiovascular risk panels — defined as multi-marker laboratory panels intended to assess cardiac risk (other than simple lipid panels) — are considered not medically necessary under this policy.

Simple lipid panels (total cholesterol, LDL-C, HDL-C, triglycerides, and certain calculated ratios) are distinct from the cardiovascular risk panels addressed here and are treated separately as routine lipid testing; examples of component CPT codes for individual tests are provided in the policy for reporting purposes.

This policy does not address use of biomarker panels for diagnosis of acute myocardial infarction and does not apply to Medicare Advantage plans.

Evidence certainty: The evidence is insufficient to determine improvement in net health outcome for cardiovascular risk panels; most studies demonstrate predictive performance rather than clinical utility.

Randomized controlled trials directly evaluating whether use of cardiovascular risk panels improves patient outcomes are described as limited or nonexistent in the evidence review; ongoing and unpublished trials are noted but do not yet establish outcome-based benefit.

Coding

Component CPT codes (may be used to report individual tests within panels)CPT

82465	Cholesterol, serum or whole blood, total.
82652	Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed.
83090	Homocysteine.
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2).
83718	Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol).
83721	Lipoprotein, direct measurement; LDL cholesterol.
83722	Lipoprotein, direct measurement; small dense LDL cholesterol.
83880	Natriuretic peptide.
84478	Triglycerides.
86141	C-reactive protein; high sensitivity (hsCRP).

1–10 of 12

1/2

There is no specific CPT code for cardiovascular risk panels. Components of testing within such panels may be reported using the individual CPT codes listed in the policy (examples include 82465, 83718, 83721, 86141, 0052U, 0119U, among others).

Providers should report individual component CPT codes when appropriate; documentation that cardiovascular risk panels are considered not medically necessary will not support coverage for routine use of such panels.

Provider Actions

Documentation Required

Do not use panels for routine risk assessment

Providers should recognize that cardiovascular risk panels (multi-biomarker panels other than simple lipid panels) are considered not medically necessary; documentation of medical necessity for coverage of such panels will not meet policy.

Billing Rule

Report individual component CPT codes when appropriate

There is no specific CPT code for cardiovascular risk panels; components of testing may be reported using the individual CPT codes listed in the policy.

82465
82652
83090
83698
83718
83721
83722
83880
84478
86141
0052U
0119U

Definitions & Background

Cardiovascular risk panels combine multiple individual biomarker tests (lipids, inflammatory markers, metabolic parameters, genetic markers, and sometimes imaging measures) intended to evaluate risk of developing cardiovascular disease. Numerous commercially available panels include different combinations of these measures.

The evidence base consists largely of observational studies, cohort and case-control data, and systematic reviews showing associations and predictive performance for many markers and panels, but studies have not demonstrated that routine use of these multi-marker panels changes management in ways that improve clinical outcomes.

Term	Definition
Simple lipid panel	Generally composed of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides; may include calculated ratios such as total/HDL cholesterol.
Cardiovascular risk panels	Panels that report results of multiple individual tests (lipids, inflammatory markers, metabolic parameters, genetic markers) intended to assess risk of developing cardiovascular disease; distinct from quantitative risk scores that combine markers.

Evidence Summary

Evidence certaintyInsufficient to determine improvement in net health outcome for cardiovascular risk panels

RCTsLimited or nonexistent for panels

Revision History

05/01/24administrative_renumbering

Policy renumbered from 2.04.100 to 2.04.509; policy statement unchanged. Codes from policy 2.04.65 moved to this policy to match BCBSA coding list.

03/01/26clarified_removed_codeLatest

Annual review updated with literature through October 28, 2025; policy statements unchanged. Removed CPT code 81291 from the policy review list as it is reviewed by Carelon.